natgillin/translations-raw huggingface dataset:
This means that it was not possible to obtain complete information about BTVPUR AlSap 1 at the time of the initial authorisation.
To pomeni, da ob prvotni odobritvi ni bilo mogoče pridobiti vseh podatkov o njem.
What is BTVPUR AlSap 1?
Kaj je zdravilo BTVPUR AlSap 1?
How has BTVPUR AlSap 1 been studied?
Kako je bilo zdravilo BTVPUR AlSap 1 raziskano?
How does BTVPUR AlSap 1 work?
Kako zdravilo BTVPUR AlSap 1 deluje?
The effectiveness of ProteqFlu-Te was first assessed in several laboratory and field studies.
Učinkovitost cepiva ProteqFlu-Te so najprej ocenili v več laboratorijskih in terenskih študijah.
Other information about ProteqFlu-Te:
Druge informacije o zdravilu ProteqFlu-Te:
The European Commission granted a marketing authorisation valid throughout the European Union, for ProteqFlu-Te on 6 March 2003.
Evropska komisija je dovoljenje za promet z zdravilom ProteqFlu-Te, veljavno po vsej Evropski uniji, izdala 6. marca 2003.
In case of increased risk of infection or insufficient intake of colostrum (first milk), an additional initial injection can be given at the age of 4 months, followed by the full vaccination programme (primary vaccination and following revaccinations).
V primeru povečanega tveganja okužbe ali nezadostnega zaužitja kolostruma (prvega mleka), se lahko pri starosti štirih mesecev injicira dodatni začetni odmerek, čemur sledi popoln program cepljenja (prvotno cepljenje, ki mu sledijo ponovitve).
The muscle stiffness usually starts from the jaw and neck, then affects the whole body.
Okorelost mišic se navadno začne v čeljusti in vratu, nato se razširi po celem telesu.
The vaccine is given as an intramuscular injection (injection into a muscle).
Cepivo se daje z intramuskularno injekcijo (vbrizganjem v mišico).
This means that a gene from two different equine influenza strains (A/eq/Ohio/03 and A/eq/Richmond/1/07) was inserted in to the canarypox vector viruses, which do not produce disease in horses, allowing the vector to produce specific proteins from these influenza strains.
To pomeni, da je bil gen iz dveh različnih sevov virusa konjske influence (A/eq/Ohio/03 in A/eq/Richmond/1/07) vstavljen v viruse vektorja canarypox, ki pri konjih ne povzroči bolezni, a omogoči vektorju, da proizvede določene beljakovine iz teh sevov influence.
ProteqFlu-Te is a vaccine for use in horses.
ProteqFlu-Te je cepivo, ki se uporablja pri konjih.
The vaccine also stimulates protection against tetanus to prevent mortality.
Cepivo spodbuja tudi zaščito pred tetanusom za preprečevanje pogina.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of ProteqFlu-Te exceed the risks for the approved indication and recommended that ProteqFlu-Te be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi cepiva ProteqFlu-Te večje od z njim povezanih tveganj, kadar se uporablja za odobrene indikacije, in priporočil, da se zanj izda dovoljenje za promet.
The vaccine also contains a tetanus toxoid which is a tetanus toxin processed in order to decrease its toxic effect, but retain its antigenic power.
Cepivo vsebuje tudi tetanusni toksoid, ki je toksin tetanusa, obdelan tako, da je njegov strupeni učinek manjši, a obdrži lastnosti antigena.
What benefit has ProteqFlu-Te shown during the studies?
Kakšne koristi je zdravilo ProteqFlu-Te izkazalo med študijami?
ProteqFlu-Te is a vaccine which was produced with the use of recombinant DNA technology.
Zdravilo ProteqFlu-Te je cepivo, izdelano s tehnologijo rekombinantne DNK.
A short lived swelling at the injection site may occur (max. diameter 5 cm) which decreases within 4 days.
Na mestu injiciranja se lahko pojavi kratkotrajna oteklina (največjega premera 5 cm), ki izgine v štirih dneh.
Horses should receive a primary vaccination, consisting of two injections at 5-6 months of age, given 4-6 weeks apart.
Konji prejmejo prvotno cepljenje, ki vključuje dve injiciranji pri starosti petih do šestih mesecev in se ju izvede v štiri- do šesttedenskem razmiku.
Tetanus is an acute, often fatal disease caused by the neurotoxin of the bacterium Clostridium tetani.
Tetanus je akutna bolezen, ki ima pogosto smrten izid, povzroča pa jo nevrotoksin bakterije Clostridium tetani.
ProteqFlu-Te contains an adjuvant (carbomer) to enhance the immune response.
Zdravilo ProteqFlu-Te vsebuje adjuvans (karbomer) za povečanje imunskega odziva.
This should be followed by revaccination 5 months later, and afterwards by booster vaccinations every two years for protection against tetanus or for protection against influenza vaccination every year alternating with ProteqFlu or ProteqFlu-Te, respecting an interval of maximum two years for tetanus.
Temu mora slediti ponovno cepljenje po petih mesecih in nato poživitvena cepljenja vsaki dve leti za zaščito pred tetanusom, za zaščito pred influenco pa morajo prejeti cepljenje vsako leto izmenjaje s cepivom ProteqFlu ali ProteqFlu-Te in ob tem upoštevati največ dveletni razmik, če gre za tetanus.
The withdrawal period is the time allowed after administration of the medicine and before the animal can be slaughtered and the meat used for consumption or milk used for consumption.
Karenca je čas, ki mora preteči po uporabi zdravila, preden se lahko žival zakolje in meso ali mleko uporabi za prehrano.
It contains parts of two equine influenza (flu) strains, which have been inserted into two canarypox vector (carrier) viruses respectively, and a tetanus toxoid (chemically weakened toxins from the tetanus bacterium).
Vsebuje dele dveh sevov virusa konjske influence (gripe), vstavljenih v dva virusa vektorja (prenašalca) canarypox, in tetanusni toksoid (kemično oslabljen toksin iz bakterije tetanusa).
The disease, which usually originates from contaminated wounds, is characterised by overall rigidity (stiffness) and convulsive spasms of the muscles.
Za bolezen, ki se navadno začne v okuženih ranah, so značilni rigidnost (otrdelost) celotnega telesa in sunkoviti krči mišic.
What is the risk associated with ProteqFlu-Te?
Kakšna tveganja so povezana z zdravilom ProteqFlu-Te?
ProteqFlu-Te is available as a suspension for injection.
Zdravilo ProteqFlu-Te je na voljo v obliki suspenzije za injiciranje.
Horses are among the most susceptible species to tetanus.
Konji spadajo med živali, ki ji tetanus najpogosteje prizadene.
The studies showed that ProteqFlu-Te was effective in reducing clinical signs and virus excretion after infection with equine influenza, and against tetanus to prevent mortality from 14 days after primary vaccination.
Študije so pokazale, da je bilo cepivo ProteqFlu-Te pri zmanjševanju kliničnih znakov in izločanju virusa po okužbi s konjsko influenco ter pri preprečevanju pogina zaradi tetanusa učinkovito 14 dni po prvotnem cepljenju.
The current formulation of ProteqFlu-Te produced similar antibody responses against the two flu strains and tetanus toxoid included in the vaccine to those seen in the main studies.
Trenutna formulacija cepiva ProteqFlu-Te je sprožila podobne odzive protiteles proti obema sevoma influence in tetanusnega toksoida, vključenim v cepivo, kot so bili tisti v glavnih študijah.
The measure of effectiveness in all studies was antibody levels of against the two influenza vaccine strains and against tetanus toxoid.
Merilo učinkovitosti v vseh študijah je bila raven protiteles proti obema sevoma virusa konjske influence in tetanusnega toksoida.
Why has ProteqFlu-Te been approved?
Zakaj je bilo zdravilo ProteqFlu-Fe odobreno?
When ProteqFlu-Te is given to horses, the animals' immune system recognises the specific proteins from the equine influenza strains and the tetanus toxoid as ‘foreign' and makes antibodies against them.
Ko konji prejmejo cepivo ProteqFlu, imunski sistem živali prepozna določene beljakovine iz sevov virusa konjske influence in toksoid tetanusa kot tujke in začne proti njim tvoriti protitelesa.
In laboratory studies, horses were challenged (infected) with equine influenza virus and the clinical signs and the excretion of the influenza virus after the challenge were compared between vaccinated and control animals (non-vaccinated animals or those vaccinated with a competitive product).
Klinične znake in izločanje virusa influence po okužbi so primerjali med cepljenimi in kontrolnimi živalmi (živalmi, ki niso bile cepljene ali so bile cepljene s konkurenčnim cepivom).
ProteqFlu-Te is used to vaccinate horses from 4 months of age against equine influenza and tetanus.
Zdravilo ProteqFlu-Te se uporablja za cepljenje konjev, starejših od štirih mesecev, proti konjski influenci in tetanusu.
The withdrawal period for ProtequFlu-Te for meat and milk is zero days.
Karenca za cepivo ProteqFlu-Fe za meso in mleko je nič dni.
The duration of protection was 5 months after primary vaccination and one year for the equine influenza and two years for the tetanus after the third vaccination.
Trajanje zaščite je bilo pet mesecev po prvotnem cepljenju, po tretjem cepljenju pa eno leto proti konjski influenci in dve leti proti tetanusu .
How has ProteqFlu-Te been studied?
Kako je bilo zdravilo ProteqFlu-Te raziskano?
What is ProteqFlu-Te used for?
Za kaj se zdravilo ProteqFlu-Te uporablja?
This will help to protect against equine influenza and tetanus.
To pomaga zaščititi živali pred konjsko influenco in tetanusom.
The immune system will then be able to make those protective antibodies more quickly when the animal is naturally exposed to the equine flu viruses and the tetanus bacterium.
Imunski sistem je nato pri naravni izpostavitvi virusom konjske gripe in bakteriji, ki povzroča tetanus, sposoben hitreje ustvarjati ta zaščitna protitelesa.
How does ProteqFlu-Te work?
Kako zdravilo ProteqFlu-Te deluje?
Equine influenza and tetanus vaccine
ProteqFlu-Te cepivo proti influenci konj in tetanusu
It may request a reexamination of the opinion within 15 days of receipt of notification of this negative opinion.
Družba lahko zahteva ponovno preučitev mnenja v 15 dneh po prejemu uradnega obvestila o negativnem mnenju.
The company presented the results of 4 main studies involving a total of 588 patients.
Družba je predložila rezultate štirih glavnih študij, v katere je bilo skupno vključenih 588 bolnikov.
Overweight men with hypogonadotropic hypogonadism produce too much of the hormone oestrogen.
Moški s čezmerno telesno maso s hipogonadotropnim hipogonadizmom proizvajajo preveč hormona estrogena.
Refusal of the marketing authorisation for EnCyzix (enclomifene) EMA/CHMP/54473/2018
Zavrnitev vloge za pridobitev dovoljenja za promet z zdravilom EnCyzix (enklomifen) EMA/CHMP/54473/2018
On 25 January 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product EnCyzix, intended for the treatment of hypogonadotropic hypogonadism in men.
Odbor za zdravila za uporabo v humani medicini (CHMP) je v svojem negativnem mnenju z dne 25. januarja 2018 priporočil zavrnitev vloge za pridobitev dovoljenja za promet z zdravilom EnCyzix, namenjenim zdravljenju hipogonadotropnega hipogonadizma pri moških.
This stops the release of other hormones called gonadotrophins, which are needed for the testes to produce testosterone and to work normally.
S tem se ustavi sproščanje drugih hormonov, imenovanih gonadotropini, ki jih moda potrebujejo za proizvodnjo testosterona in normalno delovanje.
EnCyzix was to be used in overweight men with a body mass index (BMI) of at least 25 kg/m2.
Zdravilo EnCyzix naj bi se uporabljalo pri moških s čezmerno telesno maso z indeksom telesne mase (ITM) vsaj 25 kg/m2.
Refusal of the marketing authorisation for EnCyzix (enclomifene)
Zavrnitev vloge za pridobitev dovoljenja za promet z zdravilom EnCyzix (enklomifen)
The company informed the CHMP that there are no ongoing clinical trials or compassionate use programmes with EnCyzix.
Družba je odbor CHMP obvestila, da trenutno ne potekajo klinična preskušanja ali programi sočutne uporabe zdravila EnCyzix.
EnCyzix was expected to be used to treat hypogonadotropic hypogonadism in men.
Zdravilo EnCyzix naj bi se uporabljalo za zdravljenje hipogonadotropnega hipogonadizma pri moških.
In this condition, the sex organs (the testes in men) do not work properly resulting in symptoms such as infertility, low libido, impotence, weakened bones and weight gain.
Pri tej bolezni spolni organi (tj. moda pri moških) ne delujejo pravilno, kar se kaže s simptomi, kot so neplodnost, nizek libido, impotenca, šibke kosti in pridobivanje telesne mase.
The CHMP noted that although the studies showed an increase in testosterone levels with EnCyzix, they did not look at whether EnCyzix would improve symptoms such as bone strength, weight gain, impotence and libido.
Odbor CHMP je poudaril, da so študije z zdravilom EnCyzix sicer pokazale zvišanje ravni testosterona, vendar v njih niso preučevali, ali zdravilo izboljša simptome, kot so kostna trdnost, pridobivanje telesne mase, impotenca in libido.
In addition, there is a risk of venous thromboembolism (problems due to the formation of blood clots in the veins) with the medicine.
Poleg tega zaradi zdravila obstaja tveganje za vensko trombembolijo (težave zaradi nastajanja krvnih strdkov v venah).
Therefore, the CHMP was of the opinion that the benefits of EnCyzix did not outweigh its risks and recommended that it be refused marketing authorisation.
Posledično je odbor CHMP tedaj menil, da koristi zdravila EnCyzix ne odtehtajo z njim povezanih tveganj, in priporočil, da se dovoljenje za promet z njim zavrne.
EnCyzix is a medicine that contains the active substance enclomifene.
EnCyzix je zdravilo, ki vsebuje zdravilno učinkovino enklomifen.
How does EnCyzix work?
Kako zdravilo EnCyzix deluje?
EnCyzix blocks the excess oestrogen enabling release of gonadotrophins and normal testicular function.
Zdravilo EnCyzix zavira odvečni estrogen, kar omogoča sproščanje gonadotropinov in normalno delovanje mod.
The company that applied for authorisation is Renable Pharma Limited.
Vlogo za pridobitev dovoljenja za promet z zdravilom je predložila družba Renable Pharma Limited.
What is EnCyzix?
Kaj je zdravilo EnCyzix?
What was EnCyzix expected to be used for?
Za kaj naj bi se zdravilo EnCyzix uporabljalo?
Patients were given either EnCyzix, or placebo (a dummy treatment) with and without application of a testosterone gel.
Bolniki so prejemali zdravilo EnCyzix ali placebo (zdravilo brez zdravilne učinkovine).
The main measures of effectiveness were the amount of sperm produced and testosterone levels.
Pri tem so nekateri uporabljali gel s testosteronom in drugi ne. Glavni merili učinkovitosti sta bili količina nastale sperme in raven testosterona.
The results of the two measurements were compared to see if they were in agreement.
Dobljene rezultate obeh meritev so primerjali, da bi ugotovili, ali se ujemajo.
Following this, 51 of the patients went on to be followed up for an average of three and a half more years.
Potem so 51 bolnikov spremljali še v povprečju tri leta in pol.
The European Commission granted a marketing authorisation valid throughout the European Union for Thyrogen on 9 March 2000.
Evropska komisija je dovoljenje za promet z zdravilom Thyrogen, veljavno po vsej Evropski uniji, odobrila dne 9. marca 2000.
Thyrogen must not be used during pregnancy.
Zdravilo Thyrogen se ne sme uporabljati med nosečnostjo.
The full EPAR for Thyrogen can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Thyrogen je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Thyrogen.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Thyrogen.
This finding was confirmed in the follow-up study: all 43 patients whose results could be evaluated after a further three and a half years had successful treatment.
To odkritje je potrdila študija spremljanja bolnikov: pri vseh 43 bolnikih, pri katerih je bilo rezultate mogoče vrednotiti po treh letih in pol, je bilo zdravljenje uspešno.
Thyrogen thyrotropin alfa
Thyrogen tirotropin alfa
For more information about treatment with Thyrogen, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Thyrogen preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom
The CHMP decided that Thyrogen's benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor CHMP je zaključil, da so koristi zdravila Thyrogen večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
What benefit has Thyrogen shown during the studies?
Kakšne koristi je zdravilo Thyrogen izkazalo med študijami?
The most common side effect with Thyrogen (seen in more than 1 patient in 10) is nausea (feeling sick).
Najpogostejši neželeni učinek zdravila Thyrogen (opažen pri 1 bolniku od 10) je navzeja (slabost).
This included 25 patients using Thyrogen and 18 whose replacement therapy was stopped.
V to skupino spada 25 bolnikov, ki so uporabili zdravilo Thyrogen, in 18 bolnikov s prekinitvijo nadomestnega zdravljenja.
Thyrotropin alfa is produced by a method known as ‘recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes the cell able to produce the hormone.
Tirotropin alfa proizvajajo z metodo, imenovano „tehnologija rekombinantne DNK“, pri kateri celica prejme gen (DNK), s katerim lahko tvori hormon.
For eliminating remaining thyroid tissue following thyroid cancer surgery, both treatments were 100% successful after eight months.
Pri odstranjevanju preostalega ščitničnega tkiva po operaciji ščitnice zaradi raka sta bila po osmih mesecih oba načina zdravljenja 100 % uspešna.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Thyrogen.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Thyrogen, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The iodine is given 24 hours after the last Thyrogen injection and scan is performed 48 to 72 hours later.
Jod je treba dati 24 ur po zadnji injekciji zdravila Thyrogen, slikanje pa se izvede 48 do 72 ur kasneje.
Thyrogen should not be used in people who may be hypersensitive (allergic) to bovine (cow) or human TSH or to any of the other ingredients.
Zdravila Thyrogen ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) ščitnico stimulirajoči hormon govejega ali človeškega izvora ali katero koli drugo sestavino zdravila.
In these cases, a scan will be carried out a few days later to see if there is any more thyroid tissue left.
V takšnih primerih se slikanje izvede z zamikom nekaj dni, ko se preveri, ali je ostalo še kaj ščitničnega tkiva.
However, Thyrogen has the advantage of allowing patients to remain on their replacement therapy before the test is carried out, resulting in a better quality of life, as the temporary withdrawal of the replacement therapy has transient sideeffects which cannot always be tolerated easily.
Prednost zdravila Thyrogen pa je v tem, da bolnikom omogoča, da pred izvedbo testa še vedno prejemajo nadomestno zdravljenje, kar jim zagotavlja boljšo kakovost življenja, saj ima začasna prekinitev nadomestnega zdravljenja prehodne neželene učinke, ki jih bolniki včasih težko prenašajo.
Other information about Thyrogen
Druge informacije o zdravilu Thyrogen:
The use of Thyrogen should be supervised by a doctor with expertise in thyroid cancer.
Uporabo zdravila Thyrogen mora nadzorovati zdravnik z izkušnjami na področju raka ščitnice.
Seventy-two hours after the last injection, a blood test is carried out to check for the presence of a thyroid protein called thyroglobulin, which indicates the presence of thyroid tissue.
72 ur po zadnjem injiciranju je treba opraviti krvno preiskavo, s katero se preveri prisotnost beljakovine ščitnice, imenovane tiroglobulin, ki nakazuje prisotnost ščitničnega tkiva.
To do this, measurements of thyroid stimulation (production of thyroglobulin and uptake of radioactive iodine) were taken twice: once after treatment with Thyrogen and once after the patients had stopped taking the replacement therapy that inhibits their natural TSH production.
V ta namen so meritve stimulacije ščitnice (proizvodnja tiroglobulina in privzem radioaktivnega joda) opravili dvakrat: enkrat po zdravljenju z zdravilom Thyrogen in enkrat, ko so bolniki prenehali prejemati nadomestno zdravljenje, ki onemogoča nastajanje naravnega hormona TSH.
Thyrogen is a powder that is made up into a solution for injection.
Zdravilo Thyrogen je prašek za pripravo raztopine za injiciranje.
What is the risk associated with Thyrogen?
Kakšna tveganja so povezana z zdravilom Thyrogen?
The active substance in Thyrogen, thyrotropin alfa, is a copy of TSH and is used to stimulate any remaining thyroid tissue in the body, including cancerous tissue.
Zdravilna učinkovina v zdravilu Thyrogen, tirotropin alfa, je kopija TSH in se uporablja za spodbujanje morebitnega preostalega ščitničnega tkiva v telesu, vključno z rakavimi tkivi.
The company also presented the results of studies from the published literature looking at Thyrogen's effect when it was used with a thyroglobulin test, but without a radioactive iodine scan.
Družba je predstavila tudi rezultate študij iz objavljene literature, v katerih so proučevali učinek zdravila Thyrogen pri uporabi s tiroglobulinskim testom, vendar brez slikanja z radioaktivnim jodom.
Thyrogen used with lower doses of radioactive iodine was also shown to be effective.
Tudi ko so zdravilo Thyrogen uporabili z nižjimi odmerki radioaktivnega joda, se je izkazalo za učinkovito.
Thyrogen can also be used in combination with radioactive iodine to ablate (eliminate) any remaining thyroid tissue in patients who have had all or almost all of their thyroid gland removed and whose cancer has not spread to other parts of the body.
Zdravilo Thyrogen se lahko uporablja tudi v kombinaciji z radioaktivnim jodom za odstranjevanje (uničevanje) preostalega ščitničnega tkiva pri bolnikih, ki so jim odstranili celo ali skoraj celo ščitnico in pri katerih se rak ni razširil na druge dele telesa.
The published studies showed that using Thyrogen was also effective in low-risk patients when leftover tissue was detected only by measuring thyroglobulin levels and that it was not always necessary to do a radioactive iodine scan.
Objavljene študije so pokazale, da je bila uporaba zdravila Thyrogen učinkovita tudi pri bolnikih z majhnim tveganjem, ko so odkrili ostanke tkiva samo z merjenjem ravni tiroglobulina in slikanje z radioaktivnim jodom ni bilo vedno potrebno.
This is because Thyrogen will stimulate the cells in the tissue to take up the radioactive iodine, which then eliminates them.
Zdravilo namreč spodbuja celice v tkivu, da privzamejo radioaktivni jod, ki nato te celice uniči.
It is given as two injections into the buttock muscle, 24 hours apart.
Zdravilo se daje v obliki dveh injekcij v zadnjično mišico v razmiku 24 ur.
For thyroid tissue to be detected, it needs to be active, and this requires the presence of a hormone called thyroid stimulating hormone (TSH).
Da lahko zaznamo tkivo ščitnice, ga moramo najprej aktivirati, za kar mora biti prisoten hormon, ki ga imenujemo ščitnico stimulirajoči hormon (TSH).
It contains the active substance thyrotropin alfa.
Vsebuje zdravilno učinkovino tirotropin alfa.
For the full list of all side effects reported with Thyrogen, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Thyrogen, glejte navodilo za uporabo.
The main measure of effectiveness was based on a test to see if the patient had any thyroid tissue remaining at eight months after treatment.
Glavno merilo učinkovitosti je temeljilo na kontroli osem mesecev po zdravljenju, pri kateri so ugotavljali, ali so pri bolniku še prisotni ostanki ščitničnega tkiva.